Abstract Library

#2743 Mimics of Neuroendocrine Neoplasms Identified in a Single Consultation Center between 2009 and 2019

Introduction: Immunohistochemical expression of synaptophysin (SYN), chromogranin (CgA) and cytokeratin are essential for diagnosis of NENs. Non-NENs, however, may occasionally also express NE-markers and cytokeratin and cause diagnostic difficulties.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Kasajim A

Authors: Kasajima A, Konukiewitz B, Schlitter A, Weichert W, Klöppel G,

Keywords: pitfalls, pathology diagnosis,

#2198 PD-L1 Expression and Its Clinical Relevance in Neuroendocrine Tumors of the Lung

Introduction: Immune checkpoint regulation seems to be crucial for nonneuroendocrine lung cancer patients. However, little is known in lung neuroendocrine tumors.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author: Atsuko K

Authors: Kasajima A, Ishikawa Y, Iwata A, Steiger K, Oka N,

Keywords: Lung NEN, PD-L1, Prognosis,

#1668 Classification of Lung Neuroendocrine Neoplasms (Lung-NENs) According to WHO 2010 for Gastroenteropancreatic NENs (GEP-NENs) Has Prognostic Relevance and Includes Lung-NETs G3

Introduction: The classification of lung neuroendocrine neoplasms (Lung-NENs) according to the WHO classification 2010 for GEP-NENs, including a provisional category for Lung-NET G3 with Ki67 >20%, may have prognostic implications.

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author: Kasajima A

Authors: Kasajima A, Oka N, Ishida H, Sakurada A, Kameya T,

Keywords: Lung NEN,

#1666 Prognosis and Incidence in Pancreatic and Gastrointestinal Neuroendocrine Neoplasms with Emphasis on “NET G3”: An Analysis of 198 Cases from Japan

Introduction: Prognostic impact of well differentiated pancreatic neuroendocrine neoplasms (PanNENs) with a Ki67 >20%, provisionally called NET G3, needs to be validated and compared to poorly differentiated neuroendocrine carcinomas (NECs). Moreover, the frequency of NET G3 among gastrointestinal NENs (GI-NENs) has so far not been studied.

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author: Kasajima A

Authors: Kasajima A, Tachibana T, Ishida H, Yazdani S, Konukiewitz B,

Keywords: NET G3, GEP-NEN, GI-NET,

#96 Expression of components of the mTOR pathway in gastroenteropancreatic neuroendocrine tumors

Introduction: Recently, the mammalian target of rapamycin (mTOR) inhibitors have entered late phase clinical trials in a broad variety of solid human malignancies, including neuroendocrine tumors (NETs). Since these drugs will certainly be used as routine therapeutics in the near future, it is surprising that information on the exact expression patterns of mTOR and its downstream target 4EBP1 in NETs is still lacking.

Conference: 7th Annual ENETSConcerence (2010)

Presenting Author: Atsuko K

Authors: Kasajima A, Pavel M, Darb-Esfahani S, Stenzinger A, Sasano H,

Keywords: neuroendocrine tumor, proliferation index ,